AFR
Mesoblast shares slump ahead of FDA meetingWilliam McInnes
Mesoblast's shares have slumped in early trade ahead of a scheduled meeting with the US Food and Drug Administration on Thursday.
Its shares are down 13.1 per cent to $4.23, having dropped as much as 19 per cent earlier.
In a briefing note released by the FDA ahead of the meeting, the Oncologic Drugs Advisory Committee (ODAC) appears to have cast some doubt on Mesoblast's Remestemcel-L candidate.
"FDA’s position is that the product attributes the Applicant has identified as related to potency and activity, however, do not have a demonstrated relationship to the clinical performance of specific DP lots, and that the product’s proposed immunomodulatory mechanism of action has not been demonstrated in vivo in study subjects receiving remestemcel-L," it said.
"Without a demonstrated relationship with clinical effectiveness and/or in vivo potency/activity, controlling these CQAs may not be sufficient to ensure the manufacturing process consistently produces remestemcel-L lots of acceptable quality."
- Forums
- ASX - By Stock
- MSB
- MSB Trading - Aug 2020 on
MSB Trading - Aug 2020 on, page-679
-
- There are more pages in this discussion • 1,706 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B |
Open | High | Low | Value | Volume |
$1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 21024 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 241 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 21024 | 1.090 |
3 | 56689 | 1.085 |
3 | 179856 | 1.080 |
16 | 91048 | 1.075 |
2 | 22845 | 1.070 |
Price($) | Vol. | No. |
---|---|---|
1.095 | 241 | 1 |
1.100 | 271800 | 7 |
1.105 | 10740 | 2 |
1.110 | 147919 | 6 |
1.115 | 98426 | 5 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |